Australia Approves New Alzheimer's Blood Test

The Therapeutic Goods Administration has authorised a new pTau217 blood test for earlier Alzheimer's disease detection.

Updated on Oct. 27, 2026 in Alzheimer’s

A close-up view of clear glass test tubes and a laboratory pipette on a clean, white, sterile medical workbench. — Australia's Therapeutic Goods Administration has approved a rapid pTau217 blood test, enabling significantly faster diagnosis for Alzheimer's disease across the country. AI Illustration. Upload story photo >

Live Poll

Would you choose to be tested for Alzheimer's decades before symptoms appear?

The Therapeutic Goods Administration has approved the pTau217 blood test, designed to identify Alzheimer's disease by detecting specific protein biomarkers. The test is expected to provide results in 18 minutes, significantly improving the speed of diagnosis.

Why it matters

This testing enables earlier and more accurate detection of Alzheimer's disease, which is critical for timely medical intervention. It represents a shift towards faster, biomarker-based screening for patients across the country.

The pTau217 test provides results in 18 minutes by detecting phosphorylated tau 217 protein, a biomarker linked to amyloid plaque buildup. It is one of two tests, alongside p-Tau181, now authorised by the Therapeutic Goods Administration.

The players

Therapeutic Goods Administration

This is the Australian government agency responsible for the regulation of medicines and medical devices.

Roche Diagnostics

This is a global healthcare company specialising in the development of in vitro diagnostic systems and tissue diagnostics.

Neuroscience Research Australia

This is a leading independent research centre based in Sydney that focuses on brain and nervous system diseases.

The details

The newly opened Asia-Pacific Centre of Excellence for Alzheimer's Disease Diagnosis in Sydney will spearhead the integration of these tests. This facility is a collaboration between Roche Diagnostics and Neuroscience Research Australia to enhance diagnostic capabilities.

October 2026: The Asia-Pacific Centre of Excellence for Alzheimer's Disease Diagnosis launches in Sydney.
Late 2026 to Early 2027: Clinical trials for the blood test are scheduled to take place.
April 2027 to July 2027: The rollout for general practitioner patient referrals is expected to begin.

The Big Picture

The establishment of the Asia-Pacific Centre of Excellence for Alzheimer's Disease Diagnosis marks a shift in Australian neurology, moving away from subjective cognitive testing toward objective biological markers. This aligns with global trends prioritising molecular diagnostic precision.

The introduction of this 18-minute blood test could soon allow patients to receive faster, more accurate diagnostic results through their local doctor. This shift reduces the need for lengthy, invasive procedures and allows for earlier conversations regarding treatment options.

The takeaway

Advancements in blood-based biomarkers represent a major improvement in how neurodegenerative diseases are identified. Patients should consult with their general practitioner regarding these new diagnostic options as they become available in their region.

What happens next

Clinical trials for the blood test will commence in late 2026, followed by a wide-scale rollout for doctor referrals scheduled between April and July 2027.